Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Cassie Chou, MD PhD, Simon Fraessle, Rachel Steinmetz, BSc, Reed M. Hawkins, BS, Tinh-Doan Phi, BS, Dirk Busch, Takahiro Miyazaki, Mario Q. Marcondes, MD PhD, Stanley R. Riddell, MD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 2866.

https://doi.org/10.1182/blood-2019-125960

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

Takahiro Miyazaki, Peiwen Kuo, Mekhala Maiti, Palakshi Obalapur, Murali Addepalli, Werner Rubas, Paul Sims, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2018) 132 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2018-99-115638

Published: 2018

Journal Articles

Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors

Tushar D Bhagat, PhD, Matthias Bartenstein, MD, Yiting Yu, PhD, A. Mario Q. Marcondes, MD PhD, Britta Will, PhD, Orsolya Giricz, PhD, Davendra P. Sohal, MD MPH, Ioannis Mantzaris, MD, Amittha Wickrema, PhD, Christine Mcmahon, MD, Yeung Cecilia, MD, John Greally, MB, PhD, Siddhartha Mukherjee, MD PhD, Ulrich Steidl, MD PhD, H. Joachim Deeg, MD, Amit Verma, MD

Blood (2014) 124 (21): 4379.

https://doi.org/10.1182/blood.V124.21.4379.4379

Published: 2014

Journal Articles

Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study

A. Mario Q. Marcondes, MD PhD, Mohamed L. Sorror, MD, Ekapun Karoopongse, MD, Terry Furlong, NP, Marina Lesnikova, PhD, Sabina Janciauskiene, MD, Charles A. Dinarello, MD, H. Joachim Deeg, MD

Blood (2014) 124 (21): 3927.

https://doi.org/10.1182/blood.V124.21.3927.3927

Published: 2014

Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD

Blood (2013) 122 (21): 1543.

https://doi.org/10.1182/blood.V122.21.1543.1543

Published: 2013

Journal Articles

Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects

A. Mario Q. Marcondes, MD, PhD, Ekapun Karoopongse, MD, Marina Lesnikova, PhD, Sabina Janciauskiene, MD, Charles A. Dinarello, M.D., H. Joachim Deeg, MD

Blood (2012) 120 (21): 1889.

https://doi.org/10.1182/blood.V120.21.1889.1889

Published: 2012

Journal Articles

α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI)

Ekapun Karoopongse, MD, Sabina Janciauskiene, MD, Charles A. Dinarello, M.D., H. Joachim Deeg, A. Mario Q. Marcondes, MD, PhD

Blood (2012) 120 (21): 4142.

https://doi.org/10.1182/blood.V120.21.4142.4142

Published: 2012

Journal Articles

Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease

A. Mario Q. Marcondes, MD, PhD, Laura Tabellini, John A. Hansen, MD, Charles A. Dinarello, MD, H. Joachim Deeg, MD

Blood (2010) 116 (21): 522.

https://doi.org/10.1182/blood.V116.21.522.522

Published: 2010

NARROW

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors

Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects

α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI)

Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only